Search

Displaying results 2411 - 2420 of 10000 in total
  1. Drug

    NOP-1A

    go.drugbank.com/drugs/DB15208
    Investigational

    NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).

  2. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin. … Nevertheless, because the incidence of hemostasis within a timely manner is relatively comparable between the use of thrombin alfa and the placebo treatment in patient subjects, thrombin alfa is not currently

  4. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. … Regorafenib is an orally-administered inhibitor of multiple kinases.

  5. Drug

    Bombesin

    go.drugbank.com/drugs/DB11724
    Investigational

    Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86 … -7548 in Patients With Prostate Cancer and Healthy Volunteers).

  6. Drug

    Amifostine

    go.drugbank.com/drugs/DB01143
    ApprovedInvestigational

    A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    [L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.

  8. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds

  9. Drug

    Lithium carbonate

    go.drugbank.com/drugs/DB14509
    ApprovedInvestigational

    Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Rifaximin

    go.drugbank.com/drugs/DB01220
    ApprovedInvestigational

    syndrome (IBS-D) in adult women and men. … It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel

    Categories: Heterocyclic Compounds with 4 or More Rings